NEW YORK — Medical technology incubator The DNA Medicine Institute last month was awarded a $1.5 million grant from the National Institutes of Health to develop a rapid, point-of-care fingerstick blood-based test for Factor VIII (FVIII) and Roche's hemophilia A treatment emicizumab (Hemlibra).